LENZ Therapeutics, Inc. - Common Stock LENZ 深 沪
已收盘 10-31 16:00:00 美东时间
29.72
-0.740
-2.43%
华盛通- 最 高32.00
- 今 开30.84
- 成交量 84.05万股
- 最 低 29.55
- 昨 收 30.46
- 总市值 8.37亿
- 52周最高 50.40
- 市盈率 静 --
- 换手率 2.99%
- 52周最低 16.535
- 委 比 23.08%
- 总股本 2814.62万
- 历史最高 230.79
- 量 比 0.93
- 振 幅 8.04%
- 历史最低 3.92
- 每 手 1
- 风险率 6.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Artelo Biosciences Appoints Mark Spring CFO, Effective Nov. 1
Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological
10-27 20:01
美股大行评级 | 潜在涨幅344.44%！Rani Therapeutics获Maxim Group升目标价至10美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Rani Therapeutics Hldgs"买入"评级，目标价从5美元升至10美元；韦德布什：维持Corbus Pharmaceuticals"跑赢大市"评级，目标价从31美元升至38美元
10-21 18:13
Raymond James Reiterates Outperform on LENZ Therapeutics, Raises Price Target to $50
Raymond James analyst Gary Nachman reiterates LENZ Therapeutics (NASDAQ:LENZ) with a Outperform and raises the price target from $40 to $50.
10-21 01:18
美股大行评级 | 伯恩斯坦上调阿里巴巴目标价升至200美元；麦格理上调百度评级至"跑赢大市"，目标价升至176美元
今日重点评级关注：摩根大通：维持National Energy Services"超配"评级，目标价从10美元升至19美元；Piper Sandler：维持LENZ Therapeutics"超配"评级，目标价从51美元升至67美元
10-13 11:26
Piper Sandler Maintains Overweight on LENZ Therapeutics, Raises Price Target to $67
Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Overweight and raises the price target from $51 to $67.
10-10 20:52
LENZ Therapeutics Raises $80M Through Stock Sale
LENZ Therapeutics ( ($LENZ) ) has shared an announcement. On October 7, 2025, L...
10-09 04:56
LENZ Therapeutics' VIZZ Commercially Availability In U.S.
VIZZ sample distribution initiated nationwide to Eye Care ProfessionalsCommercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025VIZZ is the first and only
09-30 20:06
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VI...
09-30 20:05
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
VIZZ, the first FDA-approved aceclidine-based eye drop, is now available to treat presbyopia in adults, improving near vision for up to 10 hours. Sample distribution to eye care professionals has begun nationwide, with commercial shipments to consumers starting in October and broad availability expected by mid-Q4 2025. VIZZ works by contracting the iris sphincter muscle, creating a pinhole effect that extends depth of focus. Clinical trials showe...
09-30 12:00
H.C. Wainwright Reaffirms Their Buy Rating on LENZ Therapeutics (LENZ)
In a report released today, Matthew Caufield from H.C. Wainwright reiterated a ...
08-22 19:25
